1. In Vivo
  2. >>Global Vision

On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster

 
• By Melanie Senior

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.  

Waiting
• Source: Shutterstock

It’s a nail-biting time for UK-based biotech Verona Pharma plc. Over 15 years since its founding, Verona will soon deliver results of a second Phase III trial of chronic obstructive pulmonary disease (COPD) hopeful ensifentrine. If it replicates the strongly positive efficacy and safety data seen in a first study, the company has a blockbuster in its hands, according to analysts. If not, Verona's survival may be at stake.

This binary outlook is typical for an asset-focused biotech. What’s less ordinary about Nasdaq-listed Verona is that it’s gearing up to compete in a huge, Big Pharma-dominated field where diagnosis...

Trial Population May Be Double Edged Sword

Verona’s broad trial population could expand ensifentrine’s target market – or reduce its chances of being approved at all. Since almost half of patients in the Enhance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.